Guangzhou LBP Medicine Science & Technology Co., Ltd. (688393.SS)
CNY 32.0
(7.02%)
CNY 32.0
(7.02%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 497.29 Million CNY | -1.99% |
| 2022 | 507.38 Million CNY | 15.58% |
| 2021 | 438.98 Million CNY | 16.93% |
| 2020 | 375.43 Million CNY | 5.71% |
| 2019 | 355.15 Million CNY | 15.95% |
| 2018 | 306.29 Million CNY | 17.59% |
| 2017 | 260.46 Million CNY | 8.01% |
| 2016 | 241.16 Million CNY | 0.0% |
| 2013 | 142.6 Million CNY | 32.72% |
| 2012 | 107.44 Million CNY | 22.49% |
| 2011 | 87.71 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 124.61 Million CNY | -0.66% |
| 2024 Q2 | 125.44 Million CNY | 23.63% |
| 2024 Q1 | 101.46 Million CNY | -28.94% |
| 2023 Q2 | 120.2 Million CNY | 32.47% |
| 2023 FY | 497.29 Million CNY | -1.99% |
| 2023 Q1 | 90.74 Million CNY | -31.8% |
| 2023 Q4 | 142.78 Million CNY | -0.54% |
| 2023 Q3 | 143.55 Million CNY | 19.42% |
| 2022 FY | 507.38 Million CNY | 15.58% |
| 2022 Q4 | 133.05 Million CNY | 0.95% |
| 2022 Q3 | 131.8 Million CNY | 7.65% |
| 2022 Q2 | 122.43 Million CNY | 1.95% |
| 2022 Q1 | 120.08 Million CNY | 7.31% |
| 2021 Q1 | 99.5 Million CNY | -10.19% |
| 2021 Q3 | 114.7 Million CNY | 1.63% |
| 2021 FY | 438.98 Million CNY | 16.93% |
| 2021 Q2 | 112.86 Million CNY | 13.43% |
| 2021 Q4 | 111.9 Million CNY | -2.44% |
| 2020 Q1 | 38.46 Million CNY | -63.34% |
| 2020 FY | 375.43 Million CNY | 5.71% |
| 2020 Q4 | 110.79 Million CNY | -7.53% |
| 2020 Q2 | 106.35 Million CNY | 176.53% |
| 2020 Q3 | 119.81 Million CNY | 12.66% |
| 2019 Q1 | 70.75 Million CNY | 0.0% |
| 2019 Q3 | 94.34 Million CNY | 10.8% |
| 2019 Q2 | 85.14 Million CNY | 20.34% |
| 2019 FY | 355.15 Million CNY | 15.95% |
| 2019 Q4 | 104.9 Million CNY | 11.19% |
| 2018 FY | 306.29 Million CNY | 17.59% |
| 2017 FY | 260.46 Million CNY | 8.01% |
| 2016 FY | 241.16 Million CNY | 0.0% |
| 2013 FY | 142.6 Million CNY | 32.72% |
| 2012 FY | 107.44 Million CNY | 22.49% |
| 2011 FY | 87.71 Million CNY | 0.0% |